Cargando…

Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials

INTRODUCTION: Interleukin-17 inhibitors are the newest class of monoclonal antibodies approved by the US Food and Drug Administration for the treatment of psoriasis. Preclinical and Phase II studies of ixekizumab, a high-affinity anti-IL-17A monoclonal antibody, have proved promising. METHODS: We co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farahnik, Benjamin, Beroukhim, Kourosh, Zhu, Tian Hao, Abrouk, Michael, Nakamura, Mio, Singh, Rasnik, Lee, Kristina, Bhutani, Tina, Koo, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799032/ https://www.ncbi.nlm.nih.gov/pubmed/26910853 http://dx.doi.org/10.1007/s13555-016-0102-0

Ejemplares similares

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule()
por: Abrouk, Michael, et al.
Publicado: (2016)

Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule()()
por: Abrouk, Michael, et al.
Publicado: (2017)

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
por: Kazemi, Tiana, et al.
Publicado: (2017)

The Patient’s Guide to Psoriasis Treatment. Part 4: Goeckerman Therapy
por: Zhu, Tian Hao, et al.
Publicado: (2016)

The Patient’s Guide to Psoriasis Treatment. Part 3: Biologic Injectables
por: Abrouk, Michael, et al.
Publicado: (2016)

The Patient’s Guide to Psoriasis Treatment. Part 1: UVB Phototherapy
por: Singh, Rasnik K., et al.
Publicado: (2016)

The Patient’s Guide to Psoriasis Treatment. Part 2: PUVA Phototherapy
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Erythrodermic psoriasis: pathophysiology and current treatment perspectives
por: Singh, Rasnik K, et al.
Publicado: (2016)

Excimer laser for the treatment of psoriasis: safety, efficacy, and patient acceptability
por: Abrouk, Michael, et al.
Publicado: (2016)

Recent advances in phototherapy for psoriasis
por: Nakamura, Mio, et al.
Publicado: (2016)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Dietary Behaviors in Psoriasis: Patient-Reported Outcomes from a U.S. National Survey
por: Afifi, Ladan, et al.
Publicado: (2017)

Influence of diet on the gut microbiome and implications for human health
por: Singh, Rasnik K., et al.
Publicado: (2017)

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Nakamura, Mio, et al.
Publicado: (2017)

Erythrodermic psoriasis after discontinuation of ixekizumab
por: Potter, Kathryn Anne, et al.
Publicado: (2017)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
por: Lobo, Yolanka, et al.
Publicado: (2020)

Ixekizumab May Improve Renal Function in Psoriasis
por: Amoruso, Giuseppe Fabrizio, et al.
Publicado: (2021)

Onset of vitiligo in a psoriasis patient on ixekizumab
por: Marasca, Claudio, et al.
Publicado: (2021)

Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis
por: Huang, He, et al.
Publicado: (2023)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
por: Blauvelt, A., et al.
Publicado: (2017)

Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies
por: Yosipovitch, Gil, et al.
Publicado: (2018)

The Successful Treatment of a Case of Linear Psoriasis with Ixekizumab
por: Ghoneim, Sara, et al.
Publicado: (2017)

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
por: Hawkes, Jason E., et al.
Publicado: (2021)

Ixekizumab for the Treatment of Acrodermatitis Continua of Hallopeau and Inverse Psoriasis
por: Xia, Rui Yuan, et al.
Publicado: (2023)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
por: Hanley, Tessa L, et al.
Publicado: (2017)

A case of pediatric psoriasis successfully and rapidly treated with ixekizumab
por: Megna, Matteo, et al.
Publicado: (2021)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
por: Megna, Matteo, et al.
Publicado: (2023)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Kirkham, Bruce W., et al.
Publicado: (2023)

Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumabtremelimumab in a cancer patient
por: Vinaixa Aranzazu, Arrieta, et al.
Publicado: (2021)

Ixekizumab for Patients with Plaque Psoriasis Affected by Multiple Sclerosis: Case report
por: Herrera-Acosta, Enrique, et al.
Publicado: (2021)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials
por: Smith, Saxon D., et al.
Publicado: (2023)

The psychosocial impact of acne, vitiligo, and psoriasis: a review
por: Nguyen, Catherine M, et al.
Publicado: (2016)

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
por: Blauvelt, Andrew, et al.
Publicado: (2017)

Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Paller, A.S., et al.
Publicado: (2020)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lk6qvn5cerov5sq8us2lcc3fv4